Clinical Trial Update: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab with or without ipilimumab as second-line therapy for recurrent stage IV squamous cell lung cancer without matching biomarker…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-01-11